Applications published 29 April 2009

Pharmaceutical compsns easy to swallow, not causing any unpleasant oral sensation and comprising particles with an active principle
Losan Pharma 2051693*

Pharmaceutical compsns comprising aripoprazole
Nobel Ilac Sanayi Ve Ticaret 2051694*

Implantable sustained drug delivery device for releasing active agents to the ostiomeatal complexes
Sinexus 2051695*

Stable liquid levetriacetam compsns and methods
Morton Grove Pharmaceuticals 2051696*

Foamable vehicle comprising dicarboxylic acid or dicarboxylic acid ester and pharmaceutical compsns thereof
Foamix 2051697*

A liposomal complex of sodium carboxymethyl beta-glucan
DMG Italia 2051698*

• Photosensitiser formulations for topical applications
CeramOptec 2051699*

• Compsns comprising calcium citrate malate and methods for making the same
Procter & Gamble 2051700*

• Compsns comprising calcium citrate malate and methods for making the same
Procter & Gamble 2051701*

• Multi-phasic pharmaceutical formulations of poorly water-soluble drugs for reduced fed/fasted variability and improved oral bioavailability
Novavax 2051702*

• Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
Cipla 2051703*

• Pharmaceutical compsn with controlled active ingredient delivery for active ingredients with good solubility in water
Evonik Roehm 2051704*

• Use of glucocorticoid receptor antagonists for treatment of infectious conditions
NV Organon 2051705*

• Transmucosal adminstration of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecy L)-1,4-benzoquinone
Santhera Pharmaceuticals (Schweiz) 2051706*

• Inhibitors of plasma kallikrein
Activesite Pharmaceuticals 2051707*

• Epitope reduction therapy
ISIS Innovation Ltd 2051708*

• Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque
Via Pharmaceuticals 2051709*

• Compsns and methods for treating, reducing, ameliorating or alleviating posterior-segment ophthalmic diseases
Bausch & Lomb 2051710*

• Thieno[3,2-C]pyridine-7-carboxylic acid derivatives
F Hoffmann-La Roche 2051711*

• Modulators of muscarinic receptors
Vertex Pharmaceuticals 2051712*

• Prevention and treatment of microbial infection
Sinclair Pharmaceuticals 2051713*

• Drug combinations for the treatment of respiratory tract diseases
Boehringer Ingelheim International 2051714*

• Modulators of muscarinic receptors
Vertex Pharmaceuticals 2051715*

• Induction of weight loss and the selective inhibition of PTP1B
Genaera 2051716*

• Replacing heart surgery by micronutrient
Niazi, Tariq 2051717*

• Mesenchymal stem cells and uses therefor
Osiris Therapeutics 2051718*

• Preparation with marine collagens for protease inhibition
Lohmann & Rauscher 2051719*

• Oocyte maturation method
Universite Libre de Bruxelles; Institut Halieutique et de Sciences Marines de l"Universite de Toliara 2051720*

• Preparation and pharmaceutical use of Euterpe oleracea (acai) extract compsns
Universidade do Estado do Rio de Janeiro 2051721*

• Method for treating diabetic vascular complications
National Yang-Ming University 2051722*

• Processes for production of Hoodia plant extracts containing steroidal glycosides
Unilever 2051723*

• A preparation for infertility treatment
Chieregati, Angelo 2051724*

• Methods of treating obesity using satiety factors
Harkness Pharmaceuticals 2051725*

• Method for treating pain and screening analgesic compounds
University of Utah Research Foundation 2051726*

• Methods for treating and limiting fibrotic disorders and keloids
The Arizona Board of Regents, a Body Corporate Acting For And Behalf Of Arizona State University 2051727*

• Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines
OM Pharma 2051728*

• Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
Aeterna Zentaris 2051729*

• Anti-H5N1 influenza activity of th antiviral protein cyanovirin
Government of the United States of America, Represented by the Secretary, Department of Health and Human Services 2051730*

• Methods of reducing the incidence of mastitis
Massey University 2051731*

• Methods of diagnosis and treatment of metabolic disorders
Diamedica 2051732*

• A pharmaceutical compsn for treating lung cancer, a method for inhibiting growth or invasion of lunch cancer and a method of treating lung cancer
Korea Research Institute of Bioscience and Biotechnology 2051733*

• Agents for blood-brain barrier delivery
Armagen Technologies 2051734*

• Conjugates comprising a GABA- or glycone compound, pharmaceutical compsns and combinations thereof as well as their use in treating CNS disorders
Ramot at Tel Aviv University 2051735*

• Compsns comprising a dissociated glucocorticoid receptor agonist and an immunosuppressive agent for treating dry eyes
Bausch & Lomb 2051736*

• A novel lactic acid formulation of MK-0457 useful for the treatment of cancer
Merck 2051737*

• Drug delivery system based on regioselectively amidated hyaluronic acid
Eurand Pharmaceuticals 2051738*

• Imaging medium comprising lactate and hyperpolarised 13C-pyruvate
GE Healthcare 2051739*

• Preparation and utility of opioid analgesics
Auspex Pharmaceuticals 2051740*

• Method and device for air disinfection and sterilisation
Drexel University 2051741*